Infinity Pharmaceuticals, Inc. (INFI)

Check out top investors' recommendation for INFI
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
5.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase IIa study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase II signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Jim Birchenough BMO Capital Markets Buy   Oct 12, '17     5.00  Oct 12, '18  N/A 
Matthew Harrison UBS Buy   Sep 21, '15   9.96  13.00  Sep 21, '16  -84.54% 
Michael Yee RBC Capital Markets Buy   Jan 08, '15   14.34    Jan 08, '16  -53.42% 
Jason Kantor Credit Suisse Buy   Dec 04, '14   15.79  22.00  Dec 04, '15  -47.50% 
Michael Yee RBC Capital Markets Buy   Oct 24, '14   12.73    Oct 24, '15  -18.22% 
Matthew Harrison UBS Buy   Sep 05, '14   14.46    Sep 05, '15  -40.18% 
Michael Yee RBC Capital Markets Buy   Sep 03, '14   15.73    Sep 03, '15  -42.72% 
Matthew Harrison UBS Buy   Jun 25, '14   12.67    Jun 25, '15  -13.89% 
Michael Yee RBC Capital Markets Buy   May 30, '14   10.10    May 30, '15  28.32% 
David Nierengarten Wedbush Securities Inc. Sell   Mar 03, '14   15.27    Mar 03, '15  -4.52% 
Ian Somaiya Piper Jaffray Buy   Jun 03, '13   16.41    Jun 03, '14  -41.93% 
Edward Tenthoff Piper Jaffray Buy   Jun 02, '13   16.41  50.00  Jun 02, '14  -38.45% 
Edward Tenthoff Piper Jaffray Buy   Feb 28, '13   41.29  53.00  Feb 28, '14  -59.99% 
Edward Tenthoff Piper Jaffray Buy   Jun 05, '11   6.69  9.00  Jun 05, '12  76.98% 
Edward Tenthoff Piper Jaffray Buy   May 08, '11   6.01  9.00  May 08, '12  121.46%